S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Investing.com - Guggenheim has raised its price target on Dianthus Therapeutics (NASDAQ:DNTH) to $92.00 from $84.00 while maintaining a Buy rating ahead of upcoming clinical trial results. The company, currently trading at $21.50, has shown strong momentum with a 3.66% gain over the past week. According to InvestingPro data, analyst consensus remains highly bullish with targets ranging from $34 to $84.
The price target increase comes as Dianthus prepares to release Phase II MaGic trial data for its claseprubart (DNTH103) treatment in generalized myasthenia gravis (gMG) in September 2025.
Guggenheim notes that claseprubart has a validated mechanism of action in gMG, targeting C1s, which theoretically could drive higher efficacy than blocking C5, though the firm acknowledges there is no strong experimental evidence supporting superior efficacy.
The research firm estimates that placebo-adjusted changes of ≥1.8 in MG-ADL and ≥2.5 in QMG would likely reach statistical significance, despite the study not being powered for efficacy.
Guggenheim assigns a 70% probability of success for the program to advance to Phase III, projecting potential upside of over 100% in an optimal scenario and approximately 50% downside in case of failure, while noting that Phase III readout in CIDP and Phase II readout in MMN remain on track for the second half of 2026.
In other recent news, Dianthus Therapeutics has been the focus of several noteworthy developments. Stifel has maintained its Buy rating and set a price target of $52.00 for the company, ahead of significant clinical data expected in September for its lead drug candidate, DNTH103, in treating Myasthenia Gravis. William Blair also initiated coverage of Dianthus Therapeutics with an Outperform rating, assigning a fair value of $47.57 per share. These ratings reflect confidence in the company’s focus on developing DNTH103, a C1s monoclonal antibody for autoimmune neuromuscular conditions.
Additionally, Dianthus Therapeutics announced the appointment of Dr. Simon Read to its Board of Directors, bringing over 30 years of biopharmaceutical experience to the company. This appointment comes as Lonnie Moulder steps down from the board, with the company acknowledging his contributions during its transition to a public entity. These developments highlight the company’s ongoing efforts in advancing its clinical trials and strengthening its leadership team. Investors will be watching closely for the upcoming Phase 2 trial results, which represent a significant milestone for Dianthus Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.